Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Headlam sells Tamworth distribution centre for £21.75m

(Sharecast News) - Headlam Group announced the sale of its Tamworth distribution centre for £21.75m on Monday, as part of its ongoing transformation plan, entering into a leaseback arrangement to retain use of the site for at least the next decade. The London-listed firm said the sale represented a significant uplift in value, with the price 153% above the centre's book value of £8.6m and 43% above its most recent market valuation of £15.2m.

It said the resulting profit would be recognised as non-underlying income.

Despite the disposal, the Tamworth site remained a key part of Headlam's UK logistics network.

The company said it had agreed to lease back the facility for 10 years, with an option to extend.

Headlam said the lease cost was in line with its current cost of debt, making the transaction broadly neutral to its underlying profit before tax.

Of the £21.75m in proceeds, £21.1m had been received in cash following simultaneous exchange and completion, with a further £0.7m to be paid once Headlam completes agreed repairs and maintenance.

The funds would initially be used to reduce drawings on the group's revolving credit facility, increasing liquidity as the transformation plan progresses.

Headlam said it was planning to issue a pre-close trading update on Tuesday.

At 0950 BST, shares in Headlam were up 0.88% at 86.76p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.